-
公开(公告)号：US20120213774A1
公开(公告)日：2012-08-23
申请号：US13402399
申请日：2012-02-22
申请人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
发明人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , C12N5/10 , A61P11/06 , C12N1/21 , C12P21/00 , A61P19/02 , A61P1/04 , C07K16/24 , C12N1/19
CPC分类号： C07K16/2866 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要： An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译： 结合IL33R的抗体，其特征在于重链可变结构域包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区，并且其中轻链可变区 结构域包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区或嵌合，人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。
-
2.发明授权公开(公告)号：US08790645B2
公开(公告)日：2014-07-29
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
IPC分类号： A61K39/395 , C07K16/00 , C07K16/30 , C07K16/28
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译： 本发明提供包含双特异性单链抗体构建体的药物组合物。 所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二 结构域结合人CD3抗原。 本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或 改善肿瘤疾病
-
3.发明授权公开(公告)号：US08609097B2
公开(公告)日：2013-12-17
申请号：US12792810
申请日：2010-06-03
申请人： Bernd Bohrmann , Ulrich Goepfert , Fiona Grueninger , Walter Huber , Hans-Willi Krell , Valeria Lifke , Olaf Mundigl , Sonja Offner , Laurence Ozmen , Michael Schraeml
发明人： Bernd Bohrmann , Ulrich Goepfert , Fiona Grueninger , Walter Huber , Hans-Willi Krell , Valeria Lifke , Olaf Mundigl , Sonja Offner , Laurence Ozmen , Michael Schraeml
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/4711 , C07K16/3053 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/40 , C07K2319/55
摘要： An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
摘要翻译： 与在丝氨酸422（pS422）磷酸化，特异性结合SEQ ID NO：9的磷酸化Tau片段和Tau pS422但不结合Tau和SEQ ID NO：17的磷酸化MCAK片段的Tau结合的抗体 。 该抗体可用于治疗Tauopathy。
-
公开(公告)号：US20110059093A1
公开(公告)日：2011-03-10
申请号：US12792810
申请日：2010-06-03
申请人： Bernd Bohrmann , Ulrich Goepfert , Fiona Grueninger , Walter Huber , Hans-Willi Krell , Valeria Lifke , Olaf Mundigl , Sonja Offner , Laurence Ozmen , Michael Schraeml
发明人： Bernd Bohrmann , Ulrich Goepfert , Fiona Grueninger , Walter Huber , Hans-Willi Krell , Valeria Lifke , Olaf Mundigl , Sonja Offner , Laurence Ozmen , Michael Schraeml
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/4711 , C07K16/3053 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/40 , C07K2319/55
摘要： An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
摘要翻译： 与在丝氨酸422（pS422）磷酸化，特异性结合SEQ ID NO：9的磷酸化Tau片段和Tau pS422但不结合Tau和SEQ ID NO：17的磷酸化MCAK片段的Tau结合的抗体 。 该抗体可用于治疗Tauopathy。
-
5.发明授权公开(公告)号：US07919089B2
公开(公告)日：2011-04-05
申请号：US10554851
申请日：2004-05-26
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Baeuerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Baeuerle
IPC分类号： A61K39/395 , C07K16/00 , C07K16/24
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译： 本发明提供包含双特异性单链抗体构建体的药物组合物。 所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二 结构域结合人CD3抗原。 本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或 改善肿瘤疾病
-
公开(公告)号：US08785153B2
公开(公告)日：2014-07-22
申请号：US13402399
申请日：2012-02-22
申请人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
发明人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
IPC分类号： C12P21/08
CPC分类号： C07K16/2866 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要： An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译： 结合IL33R的抗体，其特征在于重链可变结构域包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区，并且其中轻链可变区 结构域包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区或嵌合，人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。
-
公开(公告)号：US20110256137A1
公开(公告)日：2011-10-20
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
IPC分类号： A61K39/395 , C07H21/00 , A61P35/00 , C12P21/02 , C12N5/10 , C12N1/00 , C07K16/28 , C12N15/63
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译： 本发明提供包含双特异性单链抗体构建体的药物组合物。 所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二 结构域结合人CD3抗原。 本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或 改善肿瘤疾病
-
8.发明申请公开(公告)号：US20070081993A1
公开(公告)日：2007-04-12
申请号：US10554851
申请日：2004-05-26
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译： 本发明提供包含双特异性单链抗体构建体的药物组合物。 所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二 结构域结合人CD3抗原。 本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或 改善肿瘤疾病
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.027 秒)
